Effect of C-reactive protein reduction on paroxysmal atrial fibrillation

This publication has 26 references indexed in Scilit:

• Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)
  American Heart Journal, 2005
• Frequency of elevation of C-reactive protein in atrial fibrillation
  The American Journal of Cardiology, 2004
• Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation
  European Heart Journal, 2004
• Usefulness of Ambulatory 7-Day ECG Monitoring for the Detection of Atrial Fibrillation and Flutter After Acute Stroke and Transient Ischemic Attack
  Stroke, 2004
• New hope for the prevention of recurrent atrial fibrillation.
  Published by Oxford University Press (OUP) ,2004
• Analysis of Cause-Specific Mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study
  Circulation, 2004
• The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model
  Cardiovascular Research, 2004
• The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone
  International Journal of Cardiology, 1996
• Identification of Atrial Fibrillation Episodes in Ambulatory Electrocardiographic Recordings: Validation of a Method for Obtaining Labeled R‐R Interval Files
  Pacing and Clinical Electrophysiology, 1995
• Clinical features of paroxysmal atrial fibrillation an observation of 94 patients.
  Japanese Heart Journal, 1981